XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.3

Segment, Geographical and Other Revenue Information (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):

			Three Months Ended September 30, 2023																		Three Months Ended September 30, 2022
			Performance Enzymes						Novel Biotherapeutics						Total						Performance Enzymes						Novel Biotherapeutics						Total
Revenues:
Product revenue			$	5,395					$	—					$	5,395					$	28,042					$	—					$	28,042
Research and development revenue			3,315						567						3,882						3,104						3,324						6,428
Total revenues			8,710						567						9,277						31,146						3,324						34,470
Costs and operating expenses:
Cost of product revenue			2,249						—						2,249						9,786						—						9,786
Research and development (1)			8,146						4,377						12,523						6,782						13,855						20,637
Selling, general and administrative (1)			1,748						386						2,134						3,791						888						4,679
Restructuring charges			1,182						1,217						2,399						—						—						—
Asset impairment and other charges (2)			—						778						778						—						—						—
Total segment costs and operating expenses			13,325						6,758						20,083						20,359						14,743						35,102
Income (loss) from operations			$	(4,615)					$	(6,191)					(10,806)						$	10,787					$	(11,419)					(632)
Corporate costs (3)															(22,736)																		(7,947)
Unallocated depreciation and amortization															(1,357)																		(1,405)
Loss before income taxes															$	(34,899)																	$	(9,984)

			Nine Months Ended September 30, 2023																		Nine Months Ended September 30, 2022
			Performance Enzymes						Novel Biotherapeutics						Total						Performance Enzymes						Novel Biotherapeutics						Total
Revenues:
Product revenue			$	24,807					$	—					$	24,807					$	93,376					$	—					$	93,376
Research and development revenue			12,696						6,079						18,775						7,398						7,441						14,839
Total revenues			37,503						6,079						43,582						100,774						7,441						108,215
Costs and operating expenses:
Cost of product revenue			9,947						—						9,947						29,577						—						29,577
Research and development (1)			24,100						19,929						44,029						19,833						37,279						57,112
Selling, general and administrative (1)			6,578						1,528						8,106						11,208						2,288						13,496
Restructuring charges			1,182						1,362						2,544						—						—						—
Asset impairment and other charges (2)			—						778						778						—						—						—
Total segment costs and operating expenses			41,807						23,597						65,404						60,618						39,567						100,185
Income (loss) from operations			$	(4,304)					$	(17,518)					(21,822)						$	40,156					$	(32,126)					8,030
Corporate costs (3)															(42,890)																		(24,940)
Unallocated depreciation and amortization															(4,302)																		(3,953)
Loss before income taxes															$	(69,014)																	$	(20,863)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Impairment charge of $0.8 million is related to the goodwill allocated to the Novel Biotherapeutics segment.

(3) Corporate costs include unallocated selling, general and administrative expenses, unallocated asset impairment and restructuring charges, interest income, and other income (expense), net.

The following table provides stock-based compensation expense included in loss from operations (in thousands):

			Three Months Ended September 30,
			2023																								2022
			Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total						Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total
Stock-based compensation			$	903					$	(235)					$	1,615					$	2,283					$	1,593					$	414					$	2,524					$	4,531
			Nine Months Ended September 30,
			2023																								2022
			Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total						Performance Enzymes						Novel Biotherapeutics						Corporate cost						Total
Stock-based compensation			$	2,861					$	98					$	4,849					$	7,808					$	4,776					$	1,182					$	5,642					$	11,600

Schedule of Customers that Contributed 10% or More of Total Accounts Receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:

			Percentage of Total Revenues for the
			Three Months Ended September 30,												Nine Months Ended September 30,
			2023						2022						2023						2022
Customer A			20		%				*						*						*
Customer B			*						39		%				15		%				54		%
Customer C			*						13		%				*						*
Customer D			*						*						10		%				*
Customer E			*						*						10		%				*
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:

			Percentage of Accounts Receivables as of
			September 30, 2023						December 31, 2022
Customer B			*						53		%
Customer D			15		%				*
Customer E			*						10		%
Customer F			38		%				*
Customer G			17		%				*
* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):

			Three Months Ended September 30,												Nine Months Ended September 30,
			2023						2022						2023						2022
Revenues
Americas			$	4,278					$	4,822					$	10,798					$	12,167
EMEA			3,191						5,987						14,630						14,805
APAC			1,808						23,661						18,154						81,243
Total revenues			$	9,277					$	34,470					$	43,582					$	108,215

Schedule of Long-Lived Assets by Geographical Area

Identifiable long-lived assets by location was as follows (in thousands):

			September 30, 2023						December 31, 2022
United States			$	29,177					$	61,877

Schedule of Intangible Assets and Goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):

						Performance Enzymes						Novel Biotherapeutics						Total
Goodwill at January 1, 2023						$	2,463					$	778					$	3,241
Impairment						—						(778)						(778)
Goodwill at September 30, 2023						$	2,463					$	—					$	2,463

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

+ Details

Name:	us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration